Turkey Restructures Reimbursement Body But Is It Enough?
This article was originally published in PharmAsia News
Turkey has designated health sciences, and the pharmaceutical industry in particular, as a strategic sector to support economic development, and the government appears determined to turn the country into a regional hub by supporting production and high-value exports. The national reimbursement body has recently been restructured to promote these goals but the industry is cautious.
You may also be interested in...
Hoping to bring in more foreign investment and local production, Turkey is working hard to convince pharma and medtech companies of its attractions, but this effort is set to become even more challenging in the wake of the recent unsuccessful coup attempt and corporate worries over political instability.
Unpaid hospital debts have been hitting the Turkish medical sector for some time, but a government plan to repay less than the full amount owed has angered industry.
Turkey’s efforts to control rising rates of COVID-19 are compromising the ability of hospitals to pay their debts to medtech and pharmaceutical companies. The government has devised a payments plan, but there is catch.